Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect

Area of Science:

• Pharmacology
• Endocrinology
• Immunology

Background:

• Metformin is a primary treatment for type 2 diabetes, known for improving hyperglycemia.
• While effective for glucose control, its role in reducing cardiovascular events requires mechanistic understanding.
• Emerging evidence suggests metformin possesses direct anti-inflammatory properties beyond metabolic improvements.

Purpose of the Study:

• To review the evidence for metformin's anti-inflammatory actions.
• To explore the molecular mechanisms underlying metformin's anti-inflammatory effects.
• To discuss the clinical implications of metformin's anti-inflammatory properties.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of research on metformin's impact on inflammatory pathways.
• Examination of studies investigating nuclear factor κB (NF-κB) inhibition.

Main Results:

• Metformin improves chronic inflammation linked to metabolic dysfunction.
• Studies indicate metformin directly suppresses inflammatory responses.
• Inhibition of NF-κB, via AMP-activated protein kinase (AMPK)-dependent and independent pathways, is a key mechanism.

Conclusions:

• Metformin exhibits significant anti-inflammatory actions.
• These effects are mediated through the inhibition of key inflammatory pathways like NF-κB.
• Understanding these mechanisms may clarify metformin's cardiovascular benefits and guide future therapeutic strategies.